Quest Diagnostics (DGX)
NYSE: DGX · Health Care Services · Secaucus, NJ
Our rating: Neutral
Neutral reaffirmed at $242.95, moderate conviction, October 26, 2026.
Breaks if: This Neutral view flips to Positive if revenue growth holds at or above 8% year-over-year for two consecutive quarterly filings while net margin expands above 10.0%, confirming that the current growth rate is durable and beginning to drive operating leverage. It flips to Cautious if revenue growth decelerates below 3% year-over-year, or if net margin slips below 7.5% in any two of the next three quarterly filings — either outcome would mean the 27.8x P/E is pricing in a business trajectory that no longer exists.
Key figures
| Market value | $28.4B |
|---|---|
| Revenue, last 12 months | $11.8B |
| Net income, last 12 months | $1.1B |
| Free cash flow, last 12 months | $1.4B |
| Price to earnings | 25.2× |
| Free cash flow yield | 4.8% |
| Dividend yield | 1.3% |
| Operating margin | 14.6% |
| Return on equity | 15.2% |
| Beta to the S&P 500 | 0.16 |
| Volatility, annualized | 22.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $3.1B | 10.0% | $2.78 | $445M |
| June 30, 2026 | $3.0B | 10.2% | $2.84 | $459M |
| March 31, 2026 | $2.9B | 9.2% | $2.24 | $164M |
| December 31, 2025 | $2.8B | 7.1% | $2.18 | $307M |
| September 30, 2025 | $2.8B | 13.2% | $2.16 | $419M |
| June 30, 2025 | $2.8B | 15.2% | $2.47 | $436M |
| March 31, 2025 | $2.7B | 12.1% | $1.94 | $197M |
| December 31, 2024 | $2.6B | 14.6% | $1.95 | $341M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $3.06B: Claude 72%, Gemini 65%, Mistral 78%
- Diluted earnings per share are at least $2.18: Claude 65%, Gemini 82%, Mistral 88%
- Free cash flow for the quarter is at least $0.31B: Claude 58%, Gemini 58%, Mistral 76%
13 ledger entries and 29 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.